Work

Ketamine metabolites, clinical response, and gamma power in a randomized, placebo-controlled, crossover trial for treatment-resistant major depression

Year: 2020

Type: article

Source: Neuropsychopharmacology

DOI: 10.1038/s41386-020-0663-6

Authors: Cristan A. Farmer, Jessica R. Gilbert, Ruin Moaddel, Jomy George, Lilian Adeojo, Jacqueline Lovett, Allison C. Nugent, Bashkim Kadriu, Peixiong Yuan, Todd D. Gould, Lawrence T. Park, Carlos A. Zarate

Institutions: National Institutes of Health, National Institute of Mental Health, National Institute on Aging, University of Maryland, Baltimore, VA Maryland Health Care System

Language: English

Topic: Treatment of Major Depression

Subfield: Pharmacology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: U.S. Department of Health and Human Services, U.S. Department of Veterans Affairs, National Institutes of Health, National Institute on Aging, National Institute of Mental Health, National Institute of Biomedical Imaging and Bioengineering

Awards: G1003617941, G1082977498, G4088721472, G4308176370, G5693885523, G6941222083, G8044501885, G9000079022, G9000173367, Therapeutic Efficacy of Ketamine Metabolites for Depression Treatment

OpenAlex ID: W3015053440

FWCI: 6.213

Cites: 69

Cited by: 85

Related to: 10